Search engine for discovering works of Art, research articles, and books related to Art and Culture
Javascript must be enabled to continue!
MIRIKIZUMAB – THE EFFICACY OF TREATMENT IN INFLAMMATORY BOWEL DISEASE
View through CrossRef
Mirikizumab is a humanized monoclonal antibody directed against the p19 subunit of interleukin IL-23. In recent years, it has been the subject of numerous clinical trials as a potential new therapy for inflammatory bowel diseases, including Crohn’s disease and ulcerative colitis. Additionally, mirikizumab has been evaluated in clinical trials as a possible treatment for plaque psoriasis. Clinical trial results in ulcerative colitis led to its approval in the European Union, the United States, Canada, and Japan for the treatment of adult patients with moderately to severely active disease. Despite promising clinical trial outcomes, mirikizumab has not yet been approved for the treatment of Crohn’s disease. This review focuses on summarizing findings from clinical trials investigating mirikizumab in inflammatory bowel diseases. The information is derived from scientific publications indexed in PubMed, searched using the terms “mirikizumab” and “IL-23” and published up to February 2025, as well as from published clinical trial results on mirikizumab.
Title: MIRIKIZUMAB – THE EFFICACY OF TREATMENT IN INFLAMMATORY BOWEL DISEASE
Description:
Mirikizumab is a humanized monoclonal antibody directed against the p19 subunit of interleukin IL-23.
In recent years, it has been the subject of numerous clinical trials as a potential new therapy for inflammatory bowel diseases, including Crohn’s disease and ulcerative colitis.
Additionally, mirikizumab has been evaluated in clinical trials as a possible treatment for plaque psoriasis.
Clinical trial results in ulcerative colitis led to its approval in the European Union, the United States, Canada, and Japan for the treatment of adult patients with moderately to severely active disease.
Despite promising clinical trial outcomes, mirikizumab has not yet been approved for the treatment of Crohn’s disease.
This review focuses on summarizing findings from clinical trials investigating mirikizumab in inflammatory bowel diseases.
The information is derived from scientific publications indexed in PubMed, searched using the terms “mirikizumab” and “IL-23” and published up to February 2025, as well as from published clinical trial results on mirikizumab.
Related Results
Efficacy of mirikizumab induction therapy in inflammatory bowel disease: A systematic review and meta-analysis
Efficacy of mirikizumab induction therapy in inflammatory bowel disease: A systematic review and meta-analysis
Background:
Mirikizumab, an IL-23p19 monoclonal antibody, has emerged as a promising therapy for inflammatory bowel disease (IBD). However, the efficacy of diff...
Cardiac functions and aortic elasticity in children with inflammatory bowel disease: effect of age at disease onset
Cardiac functions and aortic elasticity in children with inflammatory bowel disease: effect of age at disease onset
AbstractAim:Childhood onset inflammatory bowel disease is more aggressive and has rapidly progressive clinical course than adult inflammatory bowel disease. Early-onset inflammator...
Risk factor analysis of enterocutaneous fistula after small bowel surgery
Risk factor analysis of enterocutaneous fistula after small bowel surgery
Abstract:
Background: ECF most frequently follows a complication of abdominal surgery, although a smaller number occur spontaneously in association with conditia
Background: Entero...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Treatment of postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome with mesalazine
Treatment of postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome with mesalazine
CONTEXT: Recent studies support the hypothesis that postinfectious irritable bowel syndrome and some irritable bowel syndrome patients display persistent signs of minor mucosal inf...
Mirikizumab: A promising breakthrough in Crohn's disease treatment
Mirikizumab: A promising breakthrough in Crohn's disease treatment
AbstractIntroductionCrohn's disease (CD) is a chronic, progressive inflammatory bowel disorder characterized by persistent inflammation and noncontiguous “skip lesions” throughout ...
Atypical Sigmoid Volvulus in an Adolescent: A Case Report and Literature Review
Atypical Sigmoid Volvulus in an Adolescent: A Case Report and Literature Review
Abstract
Introduction
Sigmoid volvulus is an underrecognized diagnosis with potentially fatal outcomes in adolescents; the current study aims to present an adolescent with mild sym...
Case Report : Caecal Endometrios is Causing Acute Small Bowel Obstruction
Case Report : Caecal Endometrios is Causing Acute Small Bowel Obstruction
<p><strong>Introduction</strong><strong>:</strong> Endometriosis in bowel is rare condition, about 12% of endometriosis cases. Most of bowel endometri...